Mukesh Ambani's company aims to open its own manufacturing plants, expanding Wyzr's product range to include TVs, washing machines, refrigerators
Interim budget, the US Federal policy decision and quarterly earnings will be the major drivers for stock markets which may also see some consolidation this week, say analysts. Besides, investors would also focus on the trading activity of foreign investors and global trends for further cues. From the macroeconomic front, the PMI (Purchasing Managers' Index) data for the manufacturing sector is scheduled to be announced on Thursday. Finance Minister Nirmala Sitharaman will present the interim budget for 2024-25 on February 1 (Thursday). The Federal Open Market Committee meeting will be held on January 30 and 31. "Market is likely to consolidate further ahead of the US Fed interest rate decision where the Fed is expected to maintain status quo and give some hint with regards to rate cut timeline. Apart from this, BoE (Bank of England) monetary policy is also due coupled with a few key economic data releases which might keep markets volatile. "Further many heavyweights would be ...
Some refineries stayed away from giving an undertaking to govt. for not importing unrefined gold from LDCs
US 10-yr treasury yield now below 4% as risk appetite increases
Results give message of political continuity and 'augur well' for macroeconomics, say brokerages
Shares of Zomato have nearly doubled this year as the company started to turn a profit after going public in 2021, prompting some of its biggest investors to lock in gains on their investments
Medicines for four rare diseases have become available at drastically cheaper rates as Indian pharma companies are now producing them reducing the reliance on expensive imported formulations, Union Health Ministry officials said on Friday. The slashing of prices comes as the ministry has prioritised action related to 13 rare diseases along with sickle cell anaemia. Drugs for four of these diseases -Tyrosinemia Type 1, Gaucher's Disease, Wilson's Disease and Dravet-Lennox Gastaut Syndrome - along with sickle cell Anemia have been approved and are being manufactured indigenously. Four more drugs for three diseases - Tablet Sapropterin for Phenylketonuria, tab Sodium Phenyl Butyrate and tablet Carglumic Acid for Hyperammonemia and Capsule Miglustat for Gaucher's disease - are under process for approval and are likely to be available by April 2024, official sources said. With these drugs being manufactured indigenously, the annual cost of Nitisinone capsules, used in the treatment of .
The Fed's dovish comments rekindled hopes of its rate-hiking campaign ending and spurred an equity rally across the globe
US bond yields retreat on signs the Federal Reserve may be done with tightening
With India poised to see a surge in domestic market inflows, the focus must shift to maximising the benefits for the economy
In the fourth quarter of FY23, 55 per cent of the respondents reported higher production levels
'Client interest' continues to support industry and helping growth of output and employment, it says
On the surface, it appears that the US markets have done exceedingly well. However, a deeper analysis reveals the gains in the domestic market to be more well-spread
Face value of Rs 1 cr, coupon rate 8.4%; paper has a tenure of 10 years with call option at the end of five years
The order has also made it mandatory for entities to declare the stock position on the relevant portal of the Department of Consumer Affairs
The rupee gained 6 paise to 82.54 against the US dollar in early trade on Monday, tracking positive trends in domestic and global markets as well as inflows of foreign funds. The dollar index is trading almost flat at 104 level with forex traders awaiting an agreement on the US debt ceiling between US President Joe Biden and Republican House Speaker Kevin McCarthy. At the interbank foreign exchange, the domestic unit opened stronger at 82.57 against the dollar and hit the highest level of 82.51. Later, it slipped to 82.54, registering a gain of 6 paise over its previous close. On Friday, the rupee closed at 82.60 against the US currency. Anand James, Chief Market Strategist at Geojit Financial Services, said in his rupee outlook that the Indian currency is likely to reach the level of 82.25 against the US currency. "Inability to float above 82.70 has elevated the risk of revisit of 82.45. Breach of the same may expose 82.2. Until this holds, we may pull back into the sideways tren
Nikhil Kamath explains to his followers why India's domestic consumption market is the place to be in the coming decade
Hero MotoCorp expects exports to contribute at least 10 per cent to the overall revenue pie in the medium to long term while aspiring to grow faster than the industry in the domestic market in next fiscal year, according to company's CFO Niranjan Gupta. At present, overseas shipments' share in the overall turnover pie is in low single digit. The country's largest two-wheeler maker, which ships its products to various geographies in Asia, Latin America and Africa, also plans to scale up its presence in the domestic premium segment. "As far as global business (exports) is concerned over the medium to longer term, we do want global business to be at least 10 per cent of our overall revenue. There are actions which are in place..," Gupta said in an analyst call. There were huge headwinds last year in a lot of key markets due to currency inflation and other factors with some of the markets like Sri Lanka even closing down, he said. "But obviously, these markets will come back and there
This has acted as a magnet for investors, and led to a record number of equity-trading and demat accounts being opened
The key risks identified by the brokerage are stretched government finances and oil prices going past $120 a barrel